EL7.AI
StocksMedium•13 November 2026•
4 min read

Hansa posts loss per share of 1.75 kronor and revenue of 143.0 million in third quarter

Key Facts

1Loss per share was 1.75 Swedish kronor in the third quarter of 2026, compared with 1.75 kronor in the corresponding period of 2025.
2Revenue was 143.0 million kronor in the third quarter of 2026, compared with 30.8 million a year earlier, as the mix changed significantly.
3Net cash from operating activities was 964.4 million kronor, compared with net cash used of 106.9 million a year earlier.
4Cash and cash equivalents were 1,337.2 million kronor on September 30, 2026, compared with 252.1 million on September 30, 2025.
5The Food and Drug Administration set December 19, 2026, as the action date for the imlifidase application.

Hansa Biopharma reported a loss per share of 1.75 Swedish kronor in the third quarter of 2026, the same loss recorded in the corresponding period of 2025, alongside revenue of 143.0 million kronor. The company said the revenue mix had changed significantly, so the comparison with the previous year was not direct. Revenue rose from 30.8 million kronor in the third quarter of 2025 as the company began recognizing revenue from its licensing agreement with SERB. The quarterly figure reflects a mix of licensing revenue and service supply related to the agreement, as well as payments collected earlier. The quarter’s results therefore highlight the deal’s impact on revenue recognition and liquidity, alongside the continued loss per share.

Licensing revenue related to SERB totaled 121.6 million kronor during the quarter and included the amortization of part of the 110 million euro upfront payment Hansa received in July. Supply and service revenue from SERB added 20.8 million kronor. The company said revenue was driven mainly by amounts recognized under the licensing agreement. The agreement closed on July 1, and Hansa then received the one-time upfront payment on July 8. The company had described the deal as a licensing transaction worth 115 million euros and said its completion strengthened its financial position and focused its strategic priorities on a potential U.S. launch, subject to approval.

The payment also affected operating cash flow: Hansa recorded a net cash inflow of 964.4 million kronor in the third quarter of 2026, compared with net cash used of 106.9 million kronor in the corresponding quarter a year earlier. The company attributed the shift to the 110 million euro upfront payment under the SERB agreement. Cash and cash equivalents stood at 1,337.2 million kronor on September 30, 2026, compared with 252.1 million kronor on September 30, 2025. The company said its current cash position is expected to support operations into the latter part of 2028. The figures show improved liquidity following completion of the agreement, while the quarterly loss per share remained at its year-earlier level.

The results come as Hansa advances the regulatory process for imlifidase, which it is seeking to market for highly sensitized kidney transplant patients. In an earlier update in July, the company said results from the European post-authorization follow-up study showed a one-year graft-failure-free survival rate of 90%. It added that the results support submitting an application to the European Medicines Agency to convert Idefirix to a full European marketing authorization. In the United States, the Food and Drug Administration set December 19, 2026, as the action date for imlifidase’s biologics license application. The chief executive said the date is an important milestone for the company and for highly sensitized patients awaiting kidney transplants in the United States.

Hansa estimates that highly sensitized patients account for 10–15% of people on kidney transplant waiting lists. The estimate places the target group in the context the company provided when announcing the U.S. agency’s action date, without determining the application’s outcome. In the previous quarterly comparison, revenue in the second quarter of 2026 was about 48.1 million kronor, compared with 49.1 million kronor in the second quarter of 2025. The company said first-half year-on-year revenue trends mainly reflected a weak first quarter. In trading after the results were announced on November 11, the stock rose 11.2% to $43.30 in premarket trading, from a previous close of $38.94 on November 10.

The company set February 11, 2027, as the publication date for its 2026 full-year report. Until then, the December 19, 2026, date marks a near-term U.S. regulatory milestone for the imlifidase application, while the February report is the next financial disclosure listed on the company’s calendar. Hansa expects its current cash to support operations into the latter part of 2028. The quarterly results show that SERB’s upfront payment was reflected in revenue, cash flow and liquidity during the period. Meanwhile, the loss per share remained at 1.75 kronor, matching the level in the third quarter of 2025.